These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16001645)

  • 41. Maintenance of medically induced remission of Crohn's disease.
    Gonvers JJ; Juillerat P; Mottet C; Pittet V; Felley C; Vader JP; Michetti P; Froehlich F
    Digestion; 2007; 76(2):116-29. PubMed ID: 18239403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.
    Markowitz J; Hyams J; Mack D; Leleiko N; Evans J; Kugathasan S; Pfefferkorn M; Mezoff A; Rosh J; Tolia V; Otley A; Griffiths A; Moyer MS; Oliva-Hemker M; Wyllie R; Rothbaum R; Bousvaros A; Del Rosario JF; Hale S; Lerer T;
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1124-9. PubMed ID: 16861053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
    Minnee RC; Stokkers P; Riemens SC; Hommes DW
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
    Ainsworth MA; Bendtzen K; Brynskov J
    Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.
    De Bie CI; Hummel TZ; Kindermann A; Kokke FT; Damen GM; Kneepkens CM; Van Rheenen PF; Schweizer JJ; Hoekstra JH; Norbruis OF; Tjon A Ten WE; Vreugdenhil AC; Deckers-Kocken JM; Gijsbers CF; Escher JC; De Ridder L
    Aliment Pharmacol Ther; 2011 Jan; 33(2):243-50. PubMed ID: 21083595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
    Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse.
    Yamamoto T; Umegae S; Kitagawa T; Matsumoto K
    Aliment Pharmacol Ther; 2004 Mar; 19(6):671-8. PubMed ID: 15023169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach.
    Margalit M; Israeli E; Shibolet O; Zigmond E; Klein A; Hemed N; Donegan JJ; Rabbani E; Goldin E; Ilan Y
    Am J Gastroenterol; 2006 Mar; 101(3):561-8. PubMed ID: 16542292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
    ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
    Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intestinal permeability test as a predictor of clinical course in Crohn's disease.
    D'Incà R; Di Leo V; Corrao G; Martines D; D'Odorico A; Mestriner C; Venturi C; Longo G; Sturniolo GC
    Am J Gastroenterol; 1999 Oct; 94(10):2956-60. PubMed ID: 10520851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review article: Medical therapy for fistulizing Crohn's disease.
    Bressler B; Sands BE
    Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab prevents Crohn's disease recurrence after ileal resection.
    Regueiro M; Schraut W; Baidoo L; Kip KE; Sepulveda AR; Pesci M; Harrison J; Plevy SE
    Gastroenterology; 2009 Feb; 136(2):441-50.e1; quiz 716. PubMed ID: 19109962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of clinical response to anti-TNF treatment by oral parameters in Crohn's disease.
    Groselj D; Grabec I; Seme K; Ihan A; Ferkolj I
    Hepatogastroenterology; 2008; 55(81):112-9. PubMed ID: 18507089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
    Kane S; Ford J; Cohen R; Wagner C
    J Clin Gastroenterol; 2009 Aug; 43(7):613-6. PubMed ID: 19142167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
    Lawrance IC
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
    [No Abstract]   [Full Text] [Related]  

  • 58. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
    Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
    Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract]   [Full Text] [Related]  

  • 60. Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment.
    Guidi L; Costanzo M; Ciarniello M; De Vitis I; Pioli C; Gatta L; Pace L; Tricerri A; Bartoloni C; Coppola L; Balistreri P; Doria G; Fedeli G; Gasbarrini GB
    Int J Immunopathol Pharmacol; 2005; 18(1):155-64. PubMed ID: 15698520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.